US00091F3047 - Common Stock
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) (
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (
FREMONT, CA - (NewMediaWire) - March 26, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) (
FREMONT, CA - (NewMediaWire) - March 21, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl BioPharma Inc. (AIBL), entered into an Agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share. The property is valued at approximately $7.6 million based on a third-party valuation.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA - (NewMediaWire) - March 19, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine. This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing...
FREMONT, CA - (NewMediaWire) - February 27, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The Company is currently marketing dietary supplements, as well as continuing to pursue clinical trials of pharmaceutical compounds; both of which are derived from the same source: Maitake Mushroom. The Company expects to initiate clinical trials at several prestigious medical institutes in the United States and Asia. Marketing and sales of dietary supplements in the US, Canada, and Asia have begun, and the Company expects revenue generation through its Fremont-based wholly-owned CDMO BioKey, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma,...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
The Company holds a U.S. patent for the same treatment
ABVC BioPharma announces acquisition of real estate in Taoyuan City, Taiwan at an estimated price of $2.96 million, through an equity transfer.
FREMONT, CA - (NewMediaWire) - February 8, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC’s botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) (
ABVC BioPharma filed a prospectus for the resale of 10.4 million common shares by selling stockholders, but it is not an offer to sell these securities.